Lumida
/UPB
⌘K
Upstream Bio Inc

Upstream Bio Inc

UPB
$5.73USD-0.35%-0.02 today

MARKET CAP

313.8M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$6
$34

AI Summary

Stalk
Sell NowMedium

UPB remains entrenched in a Stage 4 decline with price trading below its key moving averages. Medium-term bias is bearish, reinforced by a series of lower highs and lower lows and dynamic resistance at the 9/21 EMAs. Despite extreme oversold readings, recent rallies into EMAs have been rejected, supporting a Sell Now posture. A break and hold above the 21 EMA would invalidate this bearish timing edge.

  • Q2 2026 revenue $0.77M up 82.7% YoY, beat estimates by 15.4%
  • EPS loss narrowed to $0.73 vs $0.78 estimate
  • Q2 2026 net loss of $39.7M with negative earnings yield
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 16, 2026SellUPBAllison AmbroseGeneral Counsel477$6.10$313.8M-82.99%+1.42%$2.9K-2.89%Sell Now
Jun 16, 2026SellUPBAdam HoughtonChief Business Officer700$6.10$313.8M-82.99%+1.42%$4.3K-2.88%Sell Now
Jun 16, 2026SellUPBMichael GrayCFO and COO853$6.10$313.8M-82.99%+1.42%$5.2K-2.88%Sell Now
Jun 16, 2026SellUPBAaron DeykinChief Medical Officer895$6.10$313.8M-82.99%+1.42%$5.5K-2.63%Sell Now
Jun 16, 2026SellUPBEverett Rand SutherlandChief Executive Officer2,095$6.10$313.8M-82.99%+1.42%$12.8K-2.87%Sell Now
Mar 16, 2026SellUPBAllison AmbroseGeneral Counsel475$9.29$313.8M-82.99%+1.42%$4.4K-2.79%Sell Now
Mar 16, 2026SellUPBAdam HoughtonChief Business Officer699$9.29$313.8M-82.99%+1.42%$6.5K-2.80%Sell Now
Mar 16, 2026SellUPBMichael GrayCFO and COO852$9.29$313.8M-82.99%+1.42%$7.9K-2.79%Sell Now
Mar 16, 2026SellUPBAaron DeykinChief Medical Officer894$9.29$313.8M-82.99%+1.42%$8.3K-2.66%Sell Now
Mar 16, 2026SellUPBEverett Rand SutherlandChief Executive Officer2,093$9.29$313.8M-82.99%+1.42%$19.4K-2.79%Sell Now